A Pharmacological Trial With Sativex® and Gentamicin for Optimized Phamacological Treatment of Older Patients With Focus on Appetite Stimulation and Renal Risk Drugs (CanPan)

  • STATUS
    Recruiting
  • End date
    Sep 1, 2023
  • participants needed
    17
  • sponsor
    Ove Andersen
Updated on 16 October 2022
renal function

Summary

Malnutrition and inappropriate prescribing of renally excreted drugs are common among older persons and are associated with severe consequences such as complicated courses of treatment, mortality, and reduced quality of life. The overall purpose of CanPan is to optimize treatment of older persons with malnutrition with a focus on appetite stimulation and optimized prescribing of renal risk drugs.

The CanPan trial consists of two sub-studies. Substudy 1 will provide knowledge on appetite and appetite stimulation and together, sub study 1 and 2 will offer unique knowledge on how body composition, renal function and biomarkers of organ function influence pharmacokinetics for a highly lipophilic (Sativex®) and hydrophilic (Hexamycin®) drug in older medical patients with malnutrition.

Description

The CanPan trial consists of sub study 1 and sub study 2. Subjects who meet all the inclusion criteria and none of the exclusion criteria are invited to participate in both sub studies. Sub study 1 consist of trial days 1 and 2 and sub study 2 consists of trial day 3.

Sub study 1:

Sub study 1 is a double-blinded, randomized, placebo-controlled, multidose, crossover trial that evaluates the appetite stimulating effect as well as the pharmacokinetics of Sativex®. The primary purpose of sub study 1 is to 1) uncover whether Sativex® has appetite stimulating properties defined as increased energy intake compared to placebo, 2) to develop a pharmacokinetic-pharmacodynamic model, and gain knowledge about the effect of Sativex® on other markers of appetite, the intraocular pressure of the eye and safety parameters.

In sub study 1, subjects receive both Sativex® and placebo. Both Sativex® and placebo are administered as an oromucosal spray. Sativex consists of 2.7 mg tetrahydrocannabinol (THC) and 2.5 mg cannabidiol (CBD) per dose of spray (Cannabis sativa L. extract, cannabis leaf and flower). Subjects receive three dose of spray two times during a trial day. Trial day 1 is planned <14 days after inclusion and there is a 2-week break between trial days 1 and 2 due to a wash-out period. Follow-up visits/phonecalls are made on days 1, 2 and 7 after trial days 1 and 2.

Sub study 2:

Sub-study 2 is a single-dose pharmacokinetic study using gentamicin (Hexamycin®) as a renally excreted model drug. The purpose of sub study 2 is to compare the prediction accuracy of clearance estimates between eGFRpanel
(creatinine-cystatinC-beta-2_microglobulin-beta_trace_protein, eGFRcomb (creatinine-cystatinC), eGFRcreatinine (creatinine), uCrCl (24-hour urine creatinine clearance) and mGFR (measured GFR) as covariates in population based pharmacokinetic modeling of gentamicin.

On trial day 3, gentamicin is used as the model substance for a drug that is excreted > 90% renally. Gentamicin is administered as a single dose of 5 mg/kg as an intravenous injection (bolus). The marketed drug, Hexamycin® (40 mg / mL), is used for this purpose. Trial day 3 is held within 4 weeks after trial day 2. Follow-up visits are made on day 1 and 2 after trial day 3.

Details
Condition Malnutrition, Anorexia, Cannabis, Aging, Emergency Service, Hospital, Renal Function, Pharmacokinetics
Treatment Sativex
Clinical Study IdentifierNCT05503147
SponsorOve Andersen
Last Modified on16 October 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

≥65 years of age
Admitted to the acute medical department, Hvidovre Hospital
Can cooperate cognitively and physically (patient reported)
Low appetite/anorexia of ageing measures by SNAQ score ≤14
BMI ≤30 (screening)
Able to read and understand Danish
Postmenopausal defined as missed periods for at least 12 months before the start of the trial

Exclusion Criteria

Regular use of medical cannabis (patient reported)
Use of medical cannabis within 14 days at baseline (patient reported)
Recognized or suspected psychotic illness in the subject or the subjects family (medical record and patient report)
Severe personality disorders (journal)
Significant psychiatric disorder in addition to mild to moderate depression (medical record)
Allergy to the ingredients of Sativex®, placebo and Hexamycin® (patient reported)
Terminal diagnosis (journal)
Liver transplant (journal)
Chronic eGFR ≤15 mL / min2 or dialysis treatment (medical record)
High risk of nephrotoxicity due to existing drug treatment (medical assessment)
Pacemaker (journal)
Epilepsy (journal)
Recurrent seizures (journal)
Uncontrolled hypertension (journal)
Food intolerance to the ingredients in the test meals (patient-reported)
Vegetarian and vegan (patient-reported)
Unwilling to avoid driving for up to 72 hours after administration of Sativex® (patient-reported)
Unwilling to avoid alcohol 24 hours up to test days (patient-reported)
Patients with ascites ( journal)
Patients with significant edema on the days of the trial (journal / visual inspection)
In active treatment of cancer or have disseminated cancer (journal)
Known with brain - or kidney tumor (journal)
Known with angina pectoris or intermittent claudication
Known with stroke, AMI, or heart failure (NYHA III-IV) within the past 5 years (journal)
In isolation
Obs. Covid-19
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note